Metabolic Solutions Development Company

With $40m in Series A cash and led by a new, experienced executive team, Cirius Therapeutics Inc. is expanding a Phase IIb dose-finding trial of its insulin sensitizer MSDC-0602K in non-alcoholic st

Finalization of Phase III endpoints for non-alcoholic steatohepatitis (NASH) has been eagerly anticipated, but now that Intercept Pharmaceuticals Inc. has outlined a potential pathway to approval

The private US firm Metabolic Solutions Development Company (MSDC) has presented Phase IIb data for its insulin sensitiser drug candidate that it says has a novel metabolic action that should avoid th

Following revelations of cardiovascular risk associated with the widely used blockbuster diabetes drug Avandia (rosiglitazone) in 2007, the US Food and Drug Administration moved fast. Within a year,